JP Morgan has a neutral rating on the stock with target at Rs 915 per share as the company will focus on core therapies across value chain. The company plans to file 20 ANDAs per year. It expects 10-15 launches annually over the next four to five years. It expects dermatology will be a key growth driver with over 15 pending ANDAs.
Bank of America Merrill Lynch has upgraded it to buy. It has raised FY18/19 EPS by 4 percent and target at Rs 1674 per share. It says higher crude reduces risk to its GCC portfolio. It expects robust growth in Q3 profit on a low base but thinks the company will cut its FY17 sales/ order flow guidance.
Credit Suisse stays outperform rating on L&T and Sadbhav Engineering . It has outperform rating on L&T on pick-up in domestic execution, strong earnings growth.
Nomura continues to prefer Crompton over Havells India and Voltas . It is neutral on Crompton Greaves with a target of Rs 165 per share. It has a reduce call on Havells and Voltas with a target of Rs 296 and Rs 323 per share.
JP Morgan has a neutral call with potential upside from improving operating performance.It says a key risk for estimates & valuation are delay in execution of ANDA pipeline.
Ambit has a buy rating on the stock with a target of Rs 15928 per share stating that it has opportunity to grow revenues at 24 percent CAGR over next decade. It says the company has higher control over distribution justify valuation premium over Hanes.
IIFL has initiated coverage with an add recommendation with target at Rs 1660 per share as it would await opportunities to turn more constructive.
Deutsche Bank has a hold rating on the stock with a target price at Rs 290 per share as adjustment in coking coal prices looks likely in possible board meet on January 17. It says price hike implementation in thermal coal looks unlikely. It is higher than expected potential price across the board to be positive for the stock. It says for every 10 percent price hike across coking coal.
CLSA retains buy call on the stock with target at Rs 443 per share as valuations are compelling. It says demonetisation hit advertising revenues and the impact is expected to normalise by Q4.